EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cilostazol for peripheral arterial disease – a position paper from the Italian Society for Angiology and Vascular Medicine

Romeo Martini iD, Walter Ageno iD, Corrado Amato, Elisabetta Favaretto iD, Angelo Porfidia, Adriana Visonà iD

Vasa · 2024

DOI: 10.1024/0301-1526/a001114 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vasa, 2024. Verfasst von Romeo Martini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unità di Angiologia AULSS 1 Dolomiti, Ospedale San Martino, Belluno, Italy. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Cardiology. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cilostazol is a quinolinone-derivative selective phosphodiesterase inhibitor and is a platelet-aggregation inhibitor and arterial vasodilator for the symptomatic treatment of intermittent claudication (IC). Cilostazol has been shown to improve walking distance for patients with moderate to severe disabling intermittent claudication who do not respond to exercise therapy and who are not candidates for vascular surgical or endovascular procedures. Several studies evaluated the pharmacological effects of cilostazol for restenosis prevention and indicated a possible effect on re-endothelialization mediated by hepatocyte growth factor and endothelial precursor cells, as well as inhibiting smooth muscle cell proliferation and leukocyte adhesion to endothelium, thereby exerting an anti-inflammatory effect. These effects may suggest a potential effectiveness of cilostazol in preventing restenosis and promoting the long-term outcome of revascularization interventions. This review aimed to point out the role of cilostazol in treating patients with peripheral arterial disease, particularly with IC, and to explore its possible role in restenosis after lower limb revascularization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseCardiologyHumansCilostazolIntermittent ClaudicationTetrazolesVasodilator AgentsItaly

Stichwörter der Autor:innen

Cilostazolintermittent claudicationperipheral arterial diseasestenosis

Substanzen

CilostazolTetrazolesVasodilator Agents

Autor:innen und Institutionen

  • Unità di Angiologia AULSS 1 Dolomiti, Ospedale San Martino, Belluno, Italy.
  • Università degli studi dell'Insubria, Varese, Italy.
  • Unità Operativa di Angiologia, Dipartimento assistenziale integrato di medicina, Azienda ospedaliera universitaria policlinico Paolo Giaccone, Palermo, Italy.
  • Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy.
  • Servizio di Angiologia Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
  • UOC Angiologia, Azienda ULSS 2 Marca Trevigiana, Italy.

ORCID-Profile: Romeo Martini, Walter Ageno, Elisabetta Favaretto, Adriana Visonà

Zitieren

APA

Martini, R., Ageno, W., Amato, C., Favaretto, E., Porfidia, A., & Visonà, A. (2024). Cilostazol for peripheral arterial disease – a position paper from the Italian Society for Angiology and Vascular Medicine. Vasa. https://doi.org/10.1024/0301-1526/a001114

Vancouver

Martini R, Ageno W, Amato C, Favaretto E, Porfidia A, Visonà A. Cilostazol for peripheral arterial disease – a position paper from the Italian Society for Angiology and Vascular Medicine. Vasa. 2024. doi:10.1024/0301-1526/a001114

BibTeX
@article{Martini2024,
  author = {Martini, Romeo and Ageno, Walter and Amato, Corrado and Favaretto, Elisabetta and Porfidia, Angelo and Visonà, Adriana},
  title = {Cilostazol for peripheral arterial disease – a position paper from the Italian Society for Angiology and Vascular Medicine},
  journal = {Vasa},
  year = {2024},
  doi = {10.1024/0301-1526/a001114}
}
Kostenlos starten →